Home/ Stocks/ OMER

Omeros Corporation

OMER XNAS

$10.18 -0.18 (-1.69%) ▼ 15-min delayed

Open

$10.50

High

$10.59

Low

$10.04

Volume

956.7K

Market Cap

$755.80M

About Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 202 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-30,917,000	$-0.47
Q2 2025	$0	$-25,424,000	$-0.43
Q1 2025	$0	$-33,460,000	$-0.58
FY 2024	$0	$-156,815,000	$-2.70

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for OMER yet. Check out our latest market news or earnings calendar.

Get OMER Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Omeros Corporation.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.